Skip to main content

MindMed to Present at Leerink’s Global Healthcare Conference 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.84
+0.30 (0.13%)
AAPL  272.96
-1.15 (-0.42%)
AMD  206.74
-0.84 (-0.40%)
BAC  54.95
-0.38 (-0.70%)
GOOG  306.57
-2.75 (-0.89%)
META  650.31
+2.80 (0.43%)
MSFT  473.62
-1.20 (-0.25%)
NVDA  176.08
-0.21 (-0.12%)
ORCL  187.37
+2.45 (1.32%)
TSLA  476.57
+1.26 (0.27%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.